KR20100137416A - 암 치료법 - Google Patents

암 치료법 Download PDF

Info

Publication number
KR20100137416A
KR20100137416A KR1020107016717A KR20107016717A KR20100137416A KR 20100137416 A KR20100137416 A KR 20100137416A KR 1020107016717 A KR1020107016717 A KR 1020107016717A KR 20107016717 A KR20107016717 A KR 20107016717A KR 20100137416 A KR20100137416 A KR 20100137416A
Authority
KR
South Korea
Prior art keywords
cancer
hedgehog
chemotherapeutic agent
compound
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107016717A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 그레이젤
로버트 로스
존 맥도걸
Original Assignee
인피니티 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40824720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20100137416(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/965,688 external-priority patent/US7812164B2/en
Application filed by 인피니티 파마슈티칼스, 인코포레이티드 filed Critical 인피니티 파마슈티칼스, 인코포레이티드
Publication of KR20100137416A publication Critical patent/KR20100137416A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107016717A 2007-12-27 2008-12-23 암 치료법 Withdrawn KR20100137416A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US1716007P 2007-12-27 2007-12-27
US61/017,160 2007-12-27
US11/965,688 US7812164B2 (en) 2006-12-28 2007-12-27 Cyclopamine analogs
US11/965,688 2007-12-27
US11896908P 2008-12-01 2008-12-01
US61/118,969 2008-12-01

Publications (1)

Publication Number Publication Date
KR20100137416A true KR20100137416A (ko) 2010-12-30

Family

ID=40824720

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107016717A Withdrawn KR20100137416A (ko) 2007-12-27 2008-12-23 암 치료법

Country Status (16)

Country Link
US (1) US20090181997A1 (enExample)
EP (1) EP2225254A4 (enExample)
JP (1) JP2011522773A (enExample)
KR (1) KR20100137416A (enExample)
CN (1) CN101918420A (enExample)
AR (1) AR070047A1 (enExample)
AU (1) AU2008345151A1 (enExample)
BR (1) BRPI0821779A2 (enExample)
CA (1) CA2710377A1 (enExample)
CL (1) CL2008003901A1 (enExample)
IL (1) IL206632A0 (enExample)
MX (1) MX2010006991A (enExample)
PE (1) PE20091180A1 (enExample)
TW (1) TW200934784A (enExample)
WO (1) WO2009086416A1 (enExample)
ZA (1) ZA201004403B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
ES2610130T3 (es) 2007-12-27 2017-04-26 Infinity Pharmaceuticals, Inc. Métodos para reducción estereoselectiva
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
CA2750639A1 (en) * 2009-01-23 2010-07-29 Cancer Research Technology Limited Hedgehog pathway inhibitors
ES2567134T3 (es) 2009-08-05 2016-04-20 Infinity Pharmaceuticals, Inc. Transaminación enzimática de análogos de ciclopamina
KR20120053052A (ko) 2009-08-25 2012-05-24 아브락시스 바이오사이언스, 엘엘씨 헤지호그 억제제 및 탁산의 나노입자 조성물로의 조합 요법
US20110183948A1 (en) * 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
US20120010229A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Therapeutic regimens for hedgehog-associated cancers
US20120010230A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
RU2492855C2 (ru) * 2011-02-15 2013-09-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии" СО РАМН (ФГБУ "НИИ онкологии" СО РАМН) Способ комбинированного лечения немелкоклеточного рака легкого ii и iii стадии с пред- и послеоперационной химиотерапией
CA2752008A1 (en) 2011-09-13 2013-03-13 Universite De Montreal Combination therapy using ribavirin as elf4e inhibitor
CA2955384C (en) * 2014-07-17 2024-03-12 Biocurity Holdings, Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
ES3007999T3 (en) * 2015-04-21 2025-03-21 Genentech Inc Compositions and methods for prostate cancer analysis
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
CN107137406B (zh) * 2016-03-01 2021-07-02 江苏恒瑞医药股份有限公司 一种Hedgehog信号通路抑制剂在制备治疗EGFR过度表达的癌症的药物中的用途
MX381059B (es) * 2016-08-10 2025-04-01 Celgene Quanticel Res Inc Tratamiento de tumores y linfomas no de hodgkin sólidos, reincididos y/o refractarios.
AU2018247767B2 (en) 2017-04-03 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to STEAP-1
MX2020009759A (es) 2018-07-31 2020-10-08 Ascentage Pharma Suzhou Co Ltd Efecto antitumoral sinergico de un inhibidor de bcl-2 combinado con rituximab y/o bendamustina o un inhibidor de bcl-2 combinado con chop.
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
CA3095699A1 (en) 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
AU2019314624B2 (en) 2018-07-31 2022-03-03 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases
CN115282133A (zh) * 2021-12-06 2022-11-04 温州医科大学 竹红菌乙素在制备抗结肠癌药物中的应用
IL322070A (en) * 2023-01-12 2025-09-01 Sol Gel Tech Ltd Treatment and prevention of basal cell carcinoma using a topical compound containing petidagib

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US7741298B2 (en) * 1997-06-20 2010-06-22 New York University Method and compositions for inhibiting tumorigenesis
US7709454B2 (en) * 1997-06-20 2010-05-04 New York University Methods and compositions for inhibiting tumorigenesis
US6238876B1 (en) * 1997-06-20 2001-05-29 New York University Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
US6867216B1 (en) * 1998-04-09 2005-03-15 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signal pathways, compositions and uses related thereto
US7291626B1 (en) * 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6432970B2 (en) * 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
CA2339330A1 (en) * 1998-08-13 2000-02-24 University Of Southern California Methods to increase blood flow to ischemic tissue
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
US20070021493A1 (en) * 1999-09-16 2007-01-25 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
AU781524B2 (en) * 1999-10-13 2005-05-26 Johns Hopkins University School Of Medicine, The Regulators of the hedgehog pathway, compositions and uses related thereto
US6552016B1 (en) * 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6893637B1 (en) * 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
IL133809A0 (en) * 1999-12-30 2001-04-30 Yeda Res & Dev Steroidal alkaloids and pharmaceutical compositions comprising them
US6613798B1 (en) * 2000-03-30 2003-09-02 Curis, Inc. Small organic molecule regulators of cell proliferation
US7708998B2 (en) * 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
WO2002080952A2 (en) * 2001-04-09 2002-10-17 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
AUPR602401A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
JP2003192919A (ja) * 2001-10-17 2003-07-09 Asahi Denka Kogyo Kk 難燃性合成樹脂組成物
GB0221539D0 (en) * 2002-09-17 2002-10-23 Medical Res Council Methods of treatment
FR2850022B1 (fr) * 2003-01-22 2006-09-08 Centre Nat Rech Scient Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
US20080118493A1 (en) * 2003-07-15 2008-05-22 Beachy Philip A Elevated Hedgehog Pathway Activity In Digestive System Tumors, And Methods Of Treating Digestive Sytem Tumors Having Elevated Hedgehog Pathway Activity
US20080095761A1 (en) * 2003-10-01 2008-04-24 The Johns Hopkins University Hedgehog Signaling in Prostate Regeneration Neoplasia and Metastasis
US20070231828A1 (en) * 2003-10-01 2007-10-04 Johns Hopkins University Methods of predicting behavior of cancers
WO2005042700A2 (en) * 2003-10-20 2005-05-12 The Johns Hopkins University Use of hedgehog pathway inhibitors in small-cell lung cancer
EP2316832B1 (en) * 2004-08-27 2017-03-08 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
WO2006039569A1 (en) * 2004-09-30 2006-04-13 The University Of Chicago Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
EP1888105A2 (en) * 2005-05-12 2008-02-20 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
CA2625210A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20070197473A1 (en) * 2005-11-04 2007-08-23 Frankel Stanley R Methods of using SAHA and Bortezomib for treating cancer
US20090263317A1 (en) * 2005-12-15 2009-10-22 Wei Chen Method of screening the activity of the smoothened receptor to identify theraputic modulation agents or diagnose disease
AU2006337085B2 (en) * 2005-12-27 2013-12-19 Curis, Inc. Methods of using hedgehog kinase antagonists to inhibit hedgehog signaling and to treat hedgehog mediated disorders
WO2008121102A2 (en) * 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
US20110034498A1 (en) * 2006-03-24 2011-02-10 Mcgovern Karen J Dosing regimens for the treatment of cancer
CA2667821A1 (en) * 2006-10-31 2008-06-12 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Smoothened polypeptides and methods of use
WO2008057497A2 (en) * 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
TWI433674B (zh) * 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US7964590B2 (en) * 2007-03-07 2011-06-21 Infinity Discovery, Inc. Cyclopamine lactam analogs and methods of use thereof
BRPI0808663A2 (pt) * 2007-03-07 2014-08-26 Infinity Discovery Inc Análogos de cicloamina heterocíclicos e métodos de uso dos mesmos
JP5498936B2 (ja) * 2007-04-18 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション Ｓｍｏアンタゴニストであるトリアゾール誘導体
WO2009049258A1 (en) * 2007-10-12 2009-04-16 The Johns Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies
EA017918B1 (ru) * 2007-12-13 2013-04-30 СИЕНА БИОТЕК С.п.А. Антагонисты пути hedgehog и их терапевтические применения
US20100222287A1 (en) * 2007-12-27 2010-09-02 Mcgovern Karen J Therapeutic Cancer Treatments
ES2610130T3 (es) * 2007-12-27 2017-04-26 Infinity Pharmaceuticals, Inc. Métodos para reducción estereoselectiva
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
CL2009001479A1 (es) * 2008-07-02 2010-01-04 Infinity Pharmaceuticals Inc Metodo para aislar un alcaloide del veratrum desglicosilado que comprende proporcionar un material de planta veratrum, poner en contacto con una solucion acuosa y extraer el material de la planta veratrum con un solvente para proporcionar un extracto que comprende dicho alcaloide.
US20110183948A1 (en) * 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
US20120010229A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Therapeutic regimens for hedgehog-associated cancers
US20120010230A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling

Also Published As

Publication number Publication date
CN101918420A (zh) 2010-12-15
AU2008345151A1 (en) 2009-07-09
TW200934784A (en) 2009-08-16
EP2225254A1 (en) 2010-09-08
AR070047A1 (es) 2010-03-10
WO2009086416A1 (en) 2009-07-09
JP2011522773A (ja) 2011-08-04
US20090181997A1 (en) 2009-07-16
CA2710377A1 (en) 2009-07-09
IL206632A0 (en) 2010-12-30
BRPI0821779A2 (pt) 2019-09-24
EP2225254A4 (en) 2011-03-30
ZA201004403B (en) 2012-02-29
MX2010006991A (es) 2010-09-30
PE20091180A1 (es) 2009-08-26
CL2008003901A1 (es) 2009-07-24

Similar Documents

Publication Publication Date Title
KR20100137416A (ko) 암 치료법
US20100297118A1 (en) Therapeutic Cancer Treatments
EP3750530B1 (en) Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer
US20100222287A1 (en) Therapeutic Cancer Treatments
RU2695228C2 (ru) Прерывистое введение ингибитора mdm2
CN108025035B (zh) 用于治疗与etbr激活相关的癌症的组合物和方法
HK1221408A1 (zh) 用於治疗成胶质细胞瘤的组合疗法
KR102082363B1 (ko) 난소암의 치료를 위한 조합 치료
TW200838875A (en) Combination therapy with angiogenesis inhibitors
TW202508602A (zh) 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
KR20200026969A (ko) 치료제의 비경구 투여를 위한 조성물
JP2013504582A (ja) 有糸分裂阻害剤耐性癌の治療における使用のためのｎ−４（−（（３−（２−アミノ−４ピリミジニル）−２−ピリジニル）オキシ）フェニル）−４−（４−メチル−２−チエニル）−１−フタラジンアミン
KR20140040728A (ko) Pi3k 억제제 화합물을 사용한 중피종 치료 방법
CN112533610B (zh) 用于治疗腺样囊性癌的包含双氟烷基-1,4-苯并二氮杂䓬酮化合物的组合物
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
JP2018150292A (ja) がん治療
TW202434251A (zh) 治療癌症之療法
WO2023158514A1 (en) Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization
US11911374B2 (en) Methods and uses for treating cancer
US20150258139A1 (en) Methods for treatment of cancer using lipoplatin
JP6945587B2 (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
CA2993451C (en) Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
JP2018524292A (ja) オーロラキナーゼインヒビターと化学療法剤の投与

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100726

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid